Valuation: AbbVie Inc.

Market Cap 450B 394B 363B 336B 638B 42,701B 649B 4,351B 1,692B 21,074B 1,689B 1,653B 72,840B P/E 2026 *
30.7x
P/E 2027 * 23.9x
Enterprise Value 505B 442B 407B 377B 716B 47,917B 728B 4,882B 1,899B 23,648B 1,895B 1,854B 81,739B EV / Sales 2026 *
7.51x
EV / Sales 2027 * 6.82x
Free-Float
95.71%
Yield 2026 *
2.7%
Yield 2027 * 2.84%
1 day-0.04%
1 week+1.20%
Current month+1.20%
1 month+12.07%
3 months+23.39%
6 months+9.10%
Current year+11.45%
1 week 250.51
Extreme 250.51
261.64
1 month 215.37
Extreme 215.37
261.64
Current year 190.75
Extreme 190.75
261.64
1 year 184.63
Extreme 184.63
261.64
3 years 132.7
Extreme 132.7
261.64
5 years 105.56
Extreme 105.56
261.64
10 years 55.06
Extreme 55.0623
261.64
Manager TitleAgeSince
Chief Executive Officer 55 2024-06-30
Director of Finance/CFO 59 2022-06-22
Chief Tech/Sci/R&D Officer - 2024-02-29
Director TitleAgeSince
Director/Board Member 65 2012-12-31
Director/Board Member 74 2012-12-31
Director/Board Member 68 2012-12-31
Date Insider Type Main position Quantity % Market Cap.
06-29Free

Director

62 0.0000%
06-29Free

Director

134 0.0000%
05-07Free

Director

1,118 0.0001%
Change 5-day change 1-year change 3-year change Capi.($)
-0.04%+1.20%+35.72%+87.93% 450B
+2.96%+3.01%+59.87%+173.31% 1,102B
+3.05%+5.23%+72.11%+67.81% 643B
+1.12%-2.07%+27.62%+22.57% 336B
-0.71%-0.55%+28.96%+48.25% 288B
-2.41%+1.56%-27.58%-40.50% 222B
+0.45%+1.65%+25.65%+68.35% 199B
+5.21%+7.93%+21.99%+83.23% 169B
+1.48%-0.04%-4.64%-32.25% 137B
-1.39%+5.14%+13.68%+54.43% 133B
Average +0.24%+2.32%+25.34%+53.31% 367.77B
Weighted average by Cap. -0.04%+1.97%+40.76%+86.22%

Financials

2026 *2027 *
Net sales 67.24B 58.84B 54.23B 50.26B 95.42B 6,382B 96.96B 650B 253B 3,150B 252B 247B 10,886B 72.74B 63.65B 58.66B 54.37B 103B 6,904B 105B 703B 274B 3,407B 273B 267B 11,776B
Net income 14.35B 12.56B 11.58B 10.73B 20.37B 1,362B 20.7B 139B 53.98B 672B 53.89B 52.72B 2,324B 19.02B 16.65B 15.34B 14.22B 26.99B 1,805B 27.43B 184B 71.54B 891B 71.42B 69.87B 3,080B
Net Debt 54.97B 48.1B 44.33B 41.09B 78B 5,217B 79.26B 532B 207B 2,575B 206B 202B 8,899B 46.35B 40.56B 37.38B 34.65B 65.77B 4,399B 66.83B 448B 174B 2,171B 174B 170B 7,504B
Logo AbbVie Inc.
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (76.2%), Germany (2.8%), Japan (2.1%), Canada (2%), China (1.6%), France (1.3%), the United Kingdom (1%), Spain (1%), Italy (0.9%), Brazil (0.8%), Australia (0.8%), and Other (9.5%).
Employees
57,000
Date Price Change Volume
26-07-07 US$254.65 -0.04% 8,238,267
26-07-06 US$254.76 -2.42% 8,580,220
26-07-02 US$261.07 +3.99% 7,114,422
26-07-01 US$251.06 -0.23% 6,987,982
26-06-30 US$251.64 -1.05% 6,999,707
Trader
Investor
Global
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
31
Last Close Price
254.65USD
Average target price
258.32USD
Spread / Average Target
+1.44%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ABBV Stock